Tian Henghe, Cronstein Bruce N
Division of Endocrinology, Diabetes, and Metabolism, NYU Medical Center, New York, NY 10016, USA.
Bull NYU Hosp Jt Dis. 2007;65(3):168-73.
Methotrexate has been widely used for the treatment of rheumatoid arthritis (RA). The mechanisms of action of methotrexate are complex. Developed as a folic acid analogue, methotrexate inhibits purine and pyrimidine synthesis, which accounts for its efficacy in the therapy of cancer as well as for some of its toxicities. Recently, many studies have focused on the adenosine-mediated antiinflammatory effects of methotrexate. Certain aspects of methotrexate toxicities are also attributed to adenosine release. A better understanding of the mechanisms of action and toxicities of methotrexate will direct clinicians in their treatment approach and toxicity monitoring. Toward that objective, the latest developments in the pharmacokinetics, mechanism of action, pharmacogenetics, and toxicity of methotrexate are herein discussed.
甲氨蝶呤已被广泛用于治疗类风湿关节炎(RA)。甲氨蝶呤的作用机制很复杂。作为一种叶酸类似物开发的甲氨蝶呤可抑制嘌呤和嘧啶合成,这解释了其在癌症治疗中的疗效以及部分毒性。最近,许多研究集中在甲氨蝶呤的腺苷介导的抗炎作用上。甲氨蝶呤毒性的某些方面也归因于腺苷释放。更好地了解甲氨蝶呤的作用机制和毒性将指导临床医生的治疗方法和毒性监测。基于这一目标,本文讨论了甲氨蝶呤在药代动力学、作用机制、药物遗传学和毒性方面的最新进展。